ArticleWorld journal of gastroenterology2018
Yiguanjian decoction enhances fetal liver stem/progenitor cell-mediated repair of liver cirrhosis through regulation of macrophage activation state.
Article in World journal of gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 20 citations in OpenAlex.
- Hepatoprotective effects of modified Yiguanjian decoction in pregnant patients with chronic hepatitis B.American journal of translational research · 2026Article
- Extracellular vesicles from Yiguanjian-primed bone-marrow mesenchymal stem cells ameliorate chronic liver fibrosis via miR-7045-5p.Stem cell research & therapy · 2025Article
- Review
- Network pharmacology-based analysis on the key mechanisms of Yiguanjian acting on chronic hepatitis.Heliyon · 2024Article
- Liver cirrhosis: current status and treatment options using western or traditional Chinese medicine.Frontiers in pharmacology · 2024Review
- Review
- Efficacy and Safety of Yanggan Jian in Hepatitis B Virus-related Decompensated Cirrhosis: A Randomized, Double-blind, Controlled Trial.Journal of clinical and translational hepatology · 2023Article
- Ongoing involvers and promising therapeutic targets of hepatic fibrosis: The hepatic immune microenvironment.Frontiers in immunology · 2023Review
- Network Pharmacology and Molecular Docking Analyses Unveil the Mechanisms of Yiguanjian Decoction against Parkinson's Disease from Inner/Outer Brain Perspective.BioMed research international · 2022Article
- Mer Tyrosine Kinase (MERTK) modulates liver fibrosis progression and hepatocellular carcinoma development.Frontiers in immunology · 2022Article
- Yiguanjian decoction inhibits macrophage M1 polarization and attenuates hepatic fibrosis induced by CClPharmaceutical biology · 2021Article
- Comparative Network Pharmacology Analysis of Classical TCM Prescriptions for Chronic Liver Disease.Frontiers in pharmacology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate whether Yiguanjian decoction (YGJ) has an anti-liver cirrhotic effect and whether it regulates hepatic stem cell differentiation.
methodsA rat model of liver cirrhosis was established via subcutaneous injection of carbon tetrachloride (CCl
resultsFLSPC transplantation improved liver function and histopathology, and inhibited the activation of the non-canonical Wnt signaling pathway, while activating the canonical Wnt signaling pathway. YGJ enhanced the therapeutic effects of FLSPCs and also promoted the liver regeneration differentiation of FLSPCs into hepatocytes.
conclusionYGJ enhances FLSPC-mediated repair of liver cirrhosis through regulation of macrophage activation state, and YGJ in combination with stem cell transplantation may be a suitable treatment for end-stage liver cirrhosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.